Additionally, assays aimed at determining the capacity of tumor cells to form RAD51 foci when challenged with a DNA-damaging treatment have been proposed as biomarkers of response to PARP-i (NCT04780945) [145]. The gene discussed is RAD51; the disease is neoplasm.